25OH-Vitamin D3 Levels in Obesity and Metabolic Syndrome—Unaltered in Young and not Correlated to Carotid IMT in All Ages

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|21|17|2243-2249

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.21, Iss.17, 2015-05, pp. : 2243-2249

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Vitamin D and Metabolic Syndrome: Is There a Link?

By  

Current Pharmaceutical Design, Vol. 16, Iss. 30, 2010-10 ,pp. : 3417-3434

Bentham Science Publishers

Access to resources Recommend Favorite

The Genetics of Obesity and the Metabolic Syndrome

By  

Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders), Vol. 10, Iss. 2, 2010-06 ,pp. : 86-108

Bentham Science Publishers

Access to resources Recommend Favorite

25-(OH)VitD3, as a Risk Indicator in Diagnosis of Adenocarcinoma

By  

Current Drug Targets, Vol. 14, Iss. 11, 2013-10 ,pp. : 1367-1376

Bentham Science Publishers

Access to resources Recommend Favorite

The Problem of Low Levels of Vitamin D and Osteoporosis: Use of Combination Therapy with Alendronic Acid and Colecalciferol (Vitamin D3)

By Epstein Sol  

Drugs & Aging, Vol. 23, Iss. 8, 2006-01 ,pp. : 617-625

Adis International

Access to resources Recommend Favorite

Drug Combinations for Dyslipidemia and Obesity Treatment in Metabolic Syndrome

By  

Current Pharmaceutical Design, Vol. 15, Iss. 29, 2009-10 ,pp. : 3446-3462

Bentham Science Publishers

Access to resources Recommend Favorite